These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35764936)

  • 1. Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification.
    Lieshout R; Faria AVS; Peppelenbosch MP; van der Laan LJW; Verstegen MMA; Fuhler GM
    Mol Med; 2022 Jun; 28(1):74. PubMed ID: 35764936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
    Saborowski A; Vogel A; Segatto O
    Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
    Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
    Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
    Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for inducing branching morphogenesis in human cholangiocyte and cholangiocarcinoma organoids.
    Ober K; Roos FJM; van Tienderen GS; Köten K; Klaassen A; Mi W; van der Laan LJW; Verstegen MMA
    STAR Protoc; 2023 Sep; 4(3):102431. PubMed ID: 37432852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human branching cholangiocyte organoids recapitulate functional bile duct formation.
    Roos FJM; van Tienderen GS; Wu H; Bordeu I; Vinke D; Albarinos LM; Monfils K; Niesten S; Smits R; Willemse J; Rosmark O; Westergren-Thorsson G; Kunz DJ; de Wit M; French PJ; Vallier L; IJzermans JNM; Bartfai R; Marks H; Simons BD; van Royen ME; Verstegen MMA; van der Laan LJW
    Cell Stem Cell; 2022 May; 29(5):776-794.e13. PubMed ID: 35523140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.
    Khorsandi SE; Dokal AD; Rajeeve V; Britton DJ; Illingworth MS; Heaton N; Cutillas PR
    Cancer Res; 2021 Nov; 81(22):5765-5776. PubMed ID: 34551960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
    Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
    Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
    LaRocca RV; Hicks MD; Mull L; Foreman B
    J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.
    Koch M; Nickel S; Lieshout R; Lissek SM; Leskova M; van der Laan LJW; Verstegen MMA; Christ B; Pampaloni F
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
    Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Kinases as Targets for Opisthorchis viverrini- Associated Cholangiocarcinoma Therapy.
    Loilome W; Dokduang H
    Curr Pharm Des; 2017 Nov; 23(29):4281-4289. PubMed ID: 28699535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
    Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
    Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
    Dokduang H; Juntana S; Techasen A; Namwat N; Yongvanit P; Khuntikeo N; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3519-28. PubMed ID: 23812726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.